COGZF (Cogstate) ROCE %: 20.08% (As of Dec. 2025)


COGZF Cogstate Ltd COGZF
90 GF Score
Price $1.89
GF Value $1.57
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cogstate ROCE %?

Cogstate COGZF 90 ROCE % is 20.08% as of Dec. 2025. GuruFocus rates COGZF with a GF Score™ of 90/100 and a GF Value™ of $1.57 (Modestly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cogstate's annualized ROCE % for the quarter that ended in Dec. 2025 was 20.08%.

Cogstate  (OTCPK:COGZF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cogstate ROCE % Related Terms

Cogstate ROCE % Historical Data

* Premium members only.

The historical data trend for Cogstate's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate ROCE % Chart

Cogstate Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.10 29.76 7.57 16.46 28.96

Cogstate Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.34 23.50 22.60 35.11 20.08
COGZF
90GF Score
Cogstate Ltd COGZF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate ROCE % Calculation

Cogstate's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=13.984/( ( (57.838 - 12.693) + (64.774 - 13.342) )/ 2 )
=13.984/( (45.145+51.432)/ 2 )
=13.984/48.2885
=28.96 %

Cogstate's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=10.702/( ( (64.774 - 13.342) + (68.011 - 12.866) )/ 2 )
=10.702/( ( 51.432 + 55.145 )/ 2 )
=10.702/53.2885
=20.08 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 20.08% mean?
Cogstate (COGZF) has a ROCE % of 20.08% as of Dec. 2025.
Is Cogstate's ROCE % too high?
Cogstate's current ROCE % is 20.08%. The Healthcare Providers & Services industry median ROCE % is 6.41. Cogstate's value of 20.08% is 213.3% above this industry median. Overall, Cogstate has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's ROCE % compare to VEEV and BTSG?
Cogstate's ROCE % of 20.08% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Cogstate's value of 20.08% is 213.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current ROCE % of 20.08% is 213.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current ROCE % is 20.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (COGZF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.57, compared to a current price of $1.89 — trading 20.4% above its estimated fair value. The current ROCE % is 20.08% and 213.3% above the Healthcare Providers & Services industry median of 6.41. Cogstate's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cogstate (COGZF), the current ROCE % is 20.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cogstate (COGZF) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of $1.89 is trading 20.4% above its estimated GF Value™ of $1.57. GuruFocus considers Cogstate to be Modestly Overvalued.

Key valuation signals for COGZF:

  • ROCE %: 20.08%
  • GF Value™: $1.57 vs. price of $1.89 (20.4% above fair value)
  • GF Score™: 90/100 with 3 warning signs
  • Industry Position: 213.3% above the Healthcare Providers & Services median

No single metric tells the full story. See the COGZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cogstate Business Description

Other Exchanges C4B:GermanyCGS:Australia
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
90GF Score

Get the complete analysis for COGZF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.89
Price
$1.57
GF Value